Navipharm
Total Healthcare company who is responsible for human health from care to Cure.
2020
▪Launched ¡°Bicrome¡± for nose-care probiotics
of NVP-1703 in Korea
▪Signed a license-out agreement of NVP-1102 in Russia
▪Approved IND for clinical trial phase III of NVP-1805
2019
▪Approved IND for clinical trial phase III of NVP-1203
▪Launched NVP-1503 in Korea
▪Obtained individual recognition of functional ingredient
for NVP-1703 from MFDS
▪Initiated human study of functional probiotics
for NVP-1905
2018
▪Initiated human study of functional probiotics
for NVP-1704
▪Obtained Exclusive Marketing Approval
of NVP-1504 from MFDS
2017
▪Designated as ¡°Pharmaceutical Testing Laboratory¡±
by MFDS
▪Initiated human study of functional probiotics
for NVP-1702
▪Initiated human study of functional probiotics
for NVP-1703
2016
▪Relocated headquarters and Research Institute to
new company building
▪Obtained a marketing approval of NVP-1205
in Korea
2015
▪Signed a license-out agreement of NVP-0902
in Mexico
▪Obtained a marketing approval of NVP-1102
in Korea
2013
▪Signed a license-out agreement of NVP-0902
with Roche
▪Obtained a marketing approval
of NVP-0902 in Korea
2012
▪Signed a license-out agreement of NVP-1102
2011
▪Signed a license-out agreement of NVP-0902
2010
▪Signed an agreement with Thomson Reuters on providing and updating NCE & DMF Information in Korea
▪Registered as Venture Business Company and Company Affiliated Research Institute
2009
▪Moved into ¡°Gyeonggi Small and Medium Business Supporting Center¡± and established Research Institute
2008
▪Constructed and managed MFDS¡¯s Patent Informatics DB from August 2008 to December 2013
▪Founded Navipharm Co., Ltd.
